Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Amyloidosis 1

Interventions

Dexamethasone 6Calcium Dobesilate 3Lenalidomide 2Cyclophosphamide 2venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1belantamab mafodotin 1auricularum 1Thalidomide 1Melphalan 1Lisaftoclax 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1GTP Cyclohydrolase 1Drug Evaluation 1Biological Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Amyloidosis × GTP Cyclohydrolase × Clear all
NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Ascentage Pharma Group Inc.

Phase 1/2 Unknown
108 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡